29418-67-5

Basic information

• Product Name: 2-BROMOBENZHYDRAZIDE
• Synonyms: Benzoic acid, 2-bromo-, hydrazide;ASISCHEM D51117;LABOTEST-BB LT00454068;AKOS B020273;2-BROMOBENZHYDRAZIDE;2-BROMOBENZOIC ACID HYDRAZIDE;2-BROMOBENZOIC HYDRAZIDE;2-bromobenzohydrazide
• CAS NO: 29418-67-5
• Molecular Formula: C₇H₇BrN₂O
• Molecular Weight: 215.05
• EINECS: 249-614-2
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes;Benzoic acid;Bromine Compounds
• Mol File: 29418-67-5.mol
• Article Data: 53

Chemical Properties

• Melting Point: 152-154°C
• Boiling Point: 367.2 °C at 760 mmHg
• Flash Point: 175.9 °C
• Appearance: /
• Density: 1.615 g/cm³
• Vapor Pressure: 4.87E-06mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 11.92±0.10(Predicted)
• BRN: 1941021
• CAS DataBase Reference: 2-BROMOBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOBENZHYDRAZIDE(29418-67-5)
• EPA Substance Registry System: 2-BROMOBENZHYDRAZIDE(29418-67-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 29418-67-5(Hazardous Substances Data)

Usage

General Description

2-Bromobenzhydrazide is a chemical compound with the molecular formula C7H7BrN2O. It is primarily used as a building block in the synthesis of pharmaceuticals and agrochemicals. 2-Bromobenzhydrazide has been found to exhibit antimicrobial properties, and has potential applications in the development of new drugs to combat infections. It is also used in the production of dyes and pigments. Additionally, it is utilized as a reagent in organic chemistry for the preparation of various organic compounds. However, it is important to handle this compound with caution, as it is considered toxic and may cause skin and eye irritation upon contact.

InChI:InChI=1/C7H7BrN2O/c8-6-4-2-1-3-5(6)7(11)10-9/h1-4H,9H2,(H,10,11)

Upstream product

• 2142-69-0 2-bromophenyl methyl ketone 
• 88-65-3 2-bromobenzoic-acid 
• 7154-66-7 2-bromobenzoic acid chloride 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 6091-64-1 2-bromobenzoic acid ethyl ester 

Downstream Products

• 50625-50-8 2-bromo-benzoyl azide 
• 6630-33-7 ortho-bromobenzaldehyde 
• 103040-18-2 2-bromo-benzoic acid isopropylidenehydrazide 
• 61055-40-1 5-(2-Bromophenyl)-4-amino-3-mercapto-4H-1,2,4-triazole 
• 130240-21-0 C₂₈H₁₈Br₂N₄O₂ 
• 39631-31-7 N¹-(o-bromobenzoyl)-3-thiosemicarbazide 
• 351880-28-9 C₁₆H₁₅BrN₂O₃ 
• 1256575-00-4 (E)-N'-(3-(3,5,6-trichloropyridin-2-yloxy)benzylidene)-2-bromobenzohydrazide 
• 1417863-04-7 2-(1-adamantyl)-5-(2-bromophenyl)-1,3,4-oxadiazole 
• 1417863-13-8 2-(1-adamantylmethyl)-5-(2-bromophenyl)-1,3,4-oxadiazole 
• 61019-30-5 C₈H₆BrN₂OS₂^(1-)*K⁽¹⁺⁾ 
• 203268-68-2 2-mercapto-5-(2-bromophenyl)-1,3,4-oxadiazole 
• 1620752-80-8 ethyl 5-oxo-2-phenyl-1,5-dihydro-[1,2,4]triazolo[1,5-b]isoquinoline-10-carboxylate 
• 1620752-59-1 methyl 5-oxo-2-phenyl-1,5-dihydro-[1,2,4]triazolo[1,5-b]isoquinoline-10-carboxylate 

Relevant articles and documents

Iron-catalyzed oxidative amidation of acylhydrazines with amines

A new approach for amide bond formation via a mild and efficient Iron-catalyzed cross-coupling reaction of acylhydrazines and amines using TBHP as oxidant is described. This protocol is compatible with a wide range of amines and acylhydrazines. In addition, the synthetic application of the reaction is presented.

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction

Defective in cullin neddylation 1(DCN1) is a co-E3 ligase that is important for cullin neddylation. Dysregulation of DCN1 highly correlates with the development of various cancers. Herein, from the initial high-throughput screening, a novel hit compound 5a containing a phenyltriazole thiol core (IC50 value of 0.95 μM for DCN1-UBC12 interaction) was discovered. Further structure-based optimization leads to the development of SK-464 (IC50 value of 26 nM). We found that SK-464 not only directly bound to DCN1 in vitro, but also engaged cellular DCN1, suppressed the neddylation of cullin3, and hindered the migration and invasion of two DCN1-overexpressed squamous carcinoma cell lines (KYSE70 and H2170). These findings indicate that SK-464 may be a novel lead compound targeting DCN1-UBC12 interaction.

Design, synthesis and pharmacological evaluation of tricyclic derivatives as selective RXFP4 agonists

Relaxin family peptide receptors (RXFPs) are the potential therapeutic targets for neurological, cardiovascular, and metabolic indications. Among them, RXFP3 and RXFP4 (formerly known as GPR100 or GPCR142) are homologous class A G protein-coupled receptors with short N-terminal domain. Ligands of RXFP3 or RXFP4 are only limited to endogenous peptides and their analogues, and no natural product or synthetic agonists have been reported to date except for a scaffold of indole-containing derivatives as dual agonists of RXFP3 and RXFP4. In this study, a new scaffold of tricyclic derivatives represented by compound 7a was disclosed as a selective RXFP4 agonist after a high-throughput screening campaign against a diverse library of 52,000 synthetic and natural compounds. Two rounds of structural modification around this scaffold were performed focusing on three parts: 2-chlorophenyl group, 4-hydroxylphenyl group and its skeleton including cyclohexane-1,3-dione and 1,2,4-triazole group. Compound 14b with a new skeleton of 7,9-dihydro-4H-thiopyrano[3,4-d][1,2,4]triazolo[1,5-a]pyrimidin-8(5H)-one was thus obtained. The enantiomers of 7a and 14b were also resolved with their 9-(S)-conformer favoring RXFP4 agonism. Compared with 7a, compound 9-(S)-14b exhibited 2.3-fold higher efficacy and better selectivity for RXFP4 (selective ratio of RXFP4 vs. RXFP3 for 9-(S)-14b and 7a were 26.9 and 13.9, respectively).